REG - Pri0r1ty Intel Grp. - Contract to develop AI Hub for Leukemia Care

Pri0r1ty IntelligenceAnnouncement

18/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250318:nRSR0244Ba&default-theme=true

RNS Number : 0244B  Pri0r1ty Intelligence Group PLC  18 March 2025

 

18th March 2025

 

Pri0r1ty Intelligence Group PLC

("Pri0r1ty" or the "Company")

 

Pri0r1ty Secures up to £100,000 Contract with Leukaemia Care to Develop
AI-Powered Information Hub

 

Pri0r1ty Intelligence Group PLC (AIM: PR1) is pleased to announce that it has
secured a significant contract with Leukaemia Care, one of the UK's leading
blood cancer charities (registered charity number 1183890). The agreement,
worth up to £100,000, will see Pri0r1ty AI Ltd, the company's wholly owned
subsidiary, develop and implement an AI-powered information hub and website
platform designed to enhance the charity's digital capabilities and improve
the charities overall communication with donors and patients who are diagnosed
and living with leukaemia and those around them.

 

With over 10,000 people diagnosed with Leukemia in the UK each year, this
project will allow Pri0r1ty and Leukaemia Care to deliver tangible support,
particularly for those seeking additional help for the first time. Delivering
enhanced access to Leukaemia Care's sector-leading information at speed and
scale for as many patients and potential supporters as possible is a
fundamental goal of the project. Under the terms of the agreement, Pri0r1ty
will deliver in two phases:

 

Phase 1 will focus on creating an intuitive, user-focused information hub
powered by Pri0r1ty's AI technology, with a 24/7 AI assistant to guide users
to relevant information and support services. This phase will establish a
comprehensive digital platform that prioritises accessibility to information,
compliance with WCAG standards, and an enhanced user experience across
multiple devices. This initial phase will be delivered for a fee of £50,000,
part payable on signature of the agreement with the balance to be settled upon
agreed milestones.

 

Phase 2 will commence upon delivery of phase 1 and will expand the platform's
capabilities to include fundraising, and charity governance features, followed
by the integration of a custom CRM system to improve service delivery and
data-driven decision making. This phase will be delivered for an additional
fee of £50,000.

 

Leukaemia Care selected Pri0r1ty due to the Company's expertise in AI-powered
solutions and its desire to deliver cost-effective digital transformation
projects for organisations of various sizes. The charity aims to leverage
Pri0r1ty's technology to establish an easier entry-point for the organisations
essential services, simplify navigation for users, ensure key information is
easily accessible, and enhance engagement through personalised support
delivered by AI.

 

This contract represents a significant milestone for Pri0r1ty as it expands
its presence in the charity and healthcare sectors, demonstrating the
versatility of its AI platform across different industries. The project aligns
with the company's mission to deliver cutting-edge solutions that streamline
operations and enhance user experiences at an affordable price point.
Leukaemia Care will receive a year's subscription to Pri0r1ty's core SaaS
services included within their fee and Pri0r1ty believe that this project will
open up significant opportunity for further AI consultancy projects to deliver
strong additional revenue to the group.

 

Colin Dyer, Chief Executive at Leukaemia Care, said:

 

"We are looking forward to working with the team at Pri0r1ty over the coming
months and years to develop easier and more impactful ways for patients,
carers and health professionals to access our services as we develop them to
meet what is an ever-increasing demand. We have been impressed with the
creativity and enthusiasm which the Pri0r1ty team have already shown during
the planning phase of this project."

 

 

James Sheehan, CEO of Pri0r1ty, commented:

 

"We are delighted to partner with Leukaemia Care on this transformative
technology project that we believe will aid many people across the UK as well
as within the organisation. Our AI-powered solution will help the charity
better serve individuals affected by leukaemia by providing them with
personalised information and support through an intuitive digital platform.
This contract highlights the adaptability of our technology and strengthens
our position within the AI industry, demonstrating we can deliver AI solutions
that create tangible value across different sectors.

 

"The charity sector faces unique challenges in balancing resource constraints
with the need to deliver high-quality services. Our platform will enable
Leukaemia Care to enhance its digital capabilities without the need for
significant internal technical resources, allowing them to focus on their core
mission of supporting people living with leukaemia."

 

If you would like to explore how Pri0r1ty AI can help drive time and cost
efficiency for your business, please contact plc@pri0r1ty.com

 

For further information, please contact:

 

Pri0r1ty Intelligence Group PLC

James Sheehan, Chief Executive Officer

Email: ir@pri0r1ty.com

 

Nominated Adviser

Beaumont Cornish Limited

James Biddle/ Roland Cornish

Email: james@b-cornish.co.uk

Tel: +44 (0) 20 7628 3396

 

Broker

Allenby Capital Limited

Kelly Gardiner/ Jeremy Porter/ Piers Shimwell

Tel: +44 (0) 20 3328 5656

 

Financial PR Adviser

Camarco

Marc Cohen, Gabriel Hedengren, Emily Hall

Email: Pri0r1ty@camarco.co.uk

Tel: +44 (0) 20 3757 4980

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) No. 596/2014, as it forms part
of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018.
Upon the publication of this announcement, this inside information is now
considered to be in the public domain.

 

 

About Pri0r1ty Intelligence Group PLC

One of the few companies to list on AIM last year, Pri0r1ty Intelligence Group
is an AI company providing professional growth services for SMEs. As an SME,
Pri0r1ty understands the unique challenges faced by small businesses and has
developed an AI Software-as-a-Service (SaaS) platform tailored to their needs.
Pri0r1ty's platform offers cost-effective solutions that automate essential
services like social media management, investor relations, and corporate
governance. By reducing reliance on expensive external consultants, Pri0r1ty
empowers SMEs to streamline operations and focus on growth.

 

About Leukaemia Care

 

Leukaemia Care is a national blood cancer charity dedicated to ensuring that
anyone affected by leukaemia receives the right information, advice, and
support. The charity provides a range of services including a 24-hour
helpline, patient and carer support groups, and advocacy for better treatments
and care. Visit their website: https://www.leukaemiacare.org.uk/
(https://www.leukaemiacare.org.uk/)

 

Nominated Adviser Statement Beaumont Cornish Limited ("Beaumont Cornish"), is
the Company's Nominated Adviser and is authorised and regulated in the United
Kingdom by the Financial Conduct Authority. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other person for providing the protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the transaction and arrangements described in the announcement or any matter
referred to in it.

 

This information is provided by RNS, the news service of the London Stock
Exchange. RNS is approved by the Financial Conduct Authority to act as a
Primary Information Provider in the United Kingdom. Terms and conditions
relating to the use and distribution of this information may apply. For
further information, please contact rns@lseg.com or visit www.rns.com.

 

RNS may use your IP address to confirm compliance with the terms and
conditions, to analyse how you engage with the information contained in this
communication, and to share such analysis on an anonymised basis with others
as part of our commercial services. For further information about how RNS and
the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTSFAEFWEISEID